Vascular Biology |
From the Division of Biomedical Sciences, University of California, Riverside, and the Department of Bioengineering and Whitaker Institute of Biomedical Engineering, University of California, San Diego, La Jolla (S.C.), Calif.
Correspondence to Yi Zhu, MD, Division of Biomedical Sciences, University of California, Riverside, CA 92521. E-mail yi.zhu{at}ucr.edu
| Abstract |
|---|
|
|
|---|
Key Words: p38 ATF-2 Ras LDL ECs
| Introduction |
|---|
|
|
|---|
In response to stimulation by mitogens, cytokines, UV irradiation, and other environmental stresses, membrane-associated small GTPase molecules, eg, p21-Ras, are activated. Ras cycles between an active GTP-bound and an inactive GDP-bound state, functioning as a molecular switch in response to cell-activating stimuli. Ras can trigger at least 3 diverging mitogen-activated protein kinase
(MAPK) cascades. The first cascade is mediated by Raf-1 activation and transmits signals through MAPK/extracellular signal-regulated kinase (ERK) kinase
(MEK)1/2 to activate ERK. The second cascade operates through MEKK1 and JNKK to activate c-Jun NH2-terminal kinases (JNKs). The third cascade leads to p38 activation. Efficient activation of p38 requires phosphorylation of Thr-180 and Tyr-182. At least 3 Thr/Thy kinases (MKK3, MKK4/SEK1, and MKK6) phosphorylate and activate p38. This leads to the activation of multiple transcription factors, such as ATF-2 and CHOP, that induce the expression of proinflammatory genes, such as E-selectin.10
ATF-2 can form heterodimers with c-Jun, which positively regulate c-Jun promoter activity.11 Recently, we found that LDL increases AP-1 activity and activates the JNKc-Jun pathway but not the ERK/c-Fos pathway in human ECs.8 9 This report was designed to study whether LDL activates the p38ATF-2 pathway in ECs and to elucidate the upstream signaling involved. Our study demonstrates that LDL enhances Ras translocation to membrane and Ras activation in human umbilical vein ECs (HUVECs) and that these events activate both p38ATF-2 and JNKc-Jun signaling pathways. Furthermore, we show that LDL-induced E-selectin is blocked by a specific p38 inhibitor.
| Methods |
|---|
|
|
|---|
Western Blotting Analysis
Cellular membrane and cytosolic proteins from
whole-cell lysate were isolated as previously
described.12 Western
analyses with antibodies against H-Ras (Transduction
Laboratories) or Anti-ACTIVE MAPK
pAb antibody (Promega) were performed as
previously
described.9 12
Affinity Precipitation/Immunoblot
of Activated Ras
GST fusion protein, corresponding to the human
Ras-binding domain (RBD, residues 1 to 149) of Raf-1 bound to
glutathione agarose, was from Upstate
Biotechnology. The procedure used to measure Ras binding on
GSTRaf-1 RBD was described by company protocol (Upstate
Biotechnology).
ATF-2 and c-Jun Phosphorylation
Assay
The bacterial expression vector GSTATF-2 (residues
1 to 109)13 was provided by
R.J. Davis (University of Massachusetts Medical School). A GSTATF-2
fusion protein was isolated and purified. The assay for c-Jun
phosphorylation was performed as
described.9 The procedures
for the ATF-2 phosphorylation assay were similar to
those for c-Jun, except that the cell extracts were incubated with
GSTATF-2. In the study of the role of p38 on ATF-2
phosphorylation, p38 protein was immunoprecipitated
with an antibody against p38. Then, the immunoprecipitated p38 was
incubated with agarose-bound GSTATF-2 in a kinase
buffer.14
Recombinant Adenoviruses
The recombinant adenovirus Ad-RasN17 encoding for
RasN17 was constructed as described
previously.15 The
adenoviruses were plaque-purified, expanded and titrated in 293 cells,
and purified by cesium chloride
methods.16 For adenoviral
infection, confluent HUVECs were exposed to adenoviral vectors
(Ad-RasN17 or Ad-ß-gal as control) at a multiplicity of infection of
100 to 500 for 2 hours. After the viruses had been washed out, HUVECs
were continuously incubated for 18 to 24 hours before the
treatment.16
Plasmids and Transfection
For transactivation experiments, we used the
Targefect transfection method (Targeting Systems). The in vivo
trans-reporting system was purchased from
Stratagene. This system includes a pFAc-Jun,
pFCATF-2, pFA2-Elk, or pFA-CHOP (CHOP is a transcription factor
specific response to p38 activation) as an activator
plasmid, and a reporter plasmid (pFR-Luc). pFC-dbd plasmid and pFC-MEKK
plasmid were used as a negative and positive control, respectively.
pRSV-ß-gal was cotransfected as a transfection control. After 24
hours of LDL or phorbol 12-myristate 13-acetate (PMA) exposure,
samples were collected and assayed for luciferase activity. The results
were normalized against
ß-galactosidase.9
Electrophoretic Mobility Shift Assay
After infection by the adenoviral construct
Ad-RasN17, HUVEC monolayers on 100-mm dishes were exposed to 240 mg/dL
of LDL for 6 hours or to 50 ng/mL PMA for 2
hours.8 Nuclear extracts were
prepared, and an electrophoretic mobility shift assay was performed
with consensus sequences for AP-1 and nuclear factor (NF)-
B as
described.8
Northern Hybridization
Total RNA isolation and Northern analysis for
hABC1 and von Willebrand factor (vWF) expression were
performed.8 The probes of
E-selectin and vWF cDNA were labeled with
[
-32P]dCTP by DECApriming
(Ambion) as previously
described.6
Statistics
Quantitative data were expressed as mean±SEM.
Statistical significance of the data was evaluated by Students
t test. Probability values of
P<0.05 were considered
significant. For nonquantitative data, the results were expressed as
representative of
3 independent
experiments.
| Results |
|---|
|
|
|---|
|
LDL Increases ATF-2 and c-Jun Transactivation
in ECs
To further investigate whether LDL activates
ATF-2 transactivation in ECs as a consequence of p38 activation, ECs
were cotransfected with activator plasmids pFCATF-2,
pFA-CHOP, pFAc-Jun, or pFA2-Elk, and the reporter plasmid pFR-Luc.
pFC-MEKK plasmid was used as a positive control in the groups of
pFCATF-2, pFA-CHOP, and pFAc-Jun transfection. PMA was a positive
control for pFA2-Elk transfection. pFC-dbd plasmid containing the DNA
binding domain of the yeast GAL4 but lacking any activation domain
served as negative control. Eighteen hours after transfection, cells
were exposed to LDL for 24 hours, and samples were collected for
luciferase activity assay. LDL increased ATF-2 transactivation activity
by 2.8-fold, CHOP by 2.9-fold, and c-Jun by 3-fold. LDL failed to
activate pFA2-Elk, however, whereas PMA induced activity
>6-fold (see
Figure 2
). The cotransfection of pFC-dbd and pFC-luc had
only minimum luciferase activity, and LDL exposure caused no change
(data not shown).9 Thus, LDL
promotes both ATF-2 and c-Jun activation, but not Elk activation, in
human ECs. These data, together with our previous reports showing that
LDL activates
JNK/c-Jun,8 9
indicate that LDL activates ECs through both p38 and JNK
pathways.
|
LDL Increases Ras Membrane Translocation and
Activity in HUVECs
We studied whether Ras is an upstream molecule for the
activation of p38 and JNK cascades in ECs by LDL. We first examined the
membrane translocation of Ras by determining Ras abundance in
whole-cell lysates and the cell membrane. In whole-cell lysates, LDL
did not increase the amount of Ras up to 6 hours. Ras was increased by
LDL exposure in 1 to 2 hours, however, in the membrane fraction of the
cells
(Figure 3A
). Thus, LDL promotes Ras translocation to the
cytoplasmic membrane. To test Ras activation by LDL, we used GSTRaf-1
RBD conjugated with agarose to pull down the GTP-bound form of
Ras.17 The Raf-1bound Ras
was increased by LDL exposure (see
Figure 3B
). The LDL-increased Ras activation began at 30
minutes, reached a peak at 2 hours, and returned to basal level at 6
hours. These data demonstrate LDL activation of Ras in human
ECs.
|
RasN17 is a dominant negative mutant of Ras in which the
Lys-17 in the wild type has been replaced by an Asn. RasN17 competes
with the endogenous Ras and thus inhibits the Ras-mediated
signaling pathway.15 We
overexpressed the wild type of Ras (wtRas) or RasN17 in HUVECs, which
were then treated with LDL for 2 hours. The cell lysates were collected
for the GSTRaf-1 binding assay. Raf-1bound Ras in cells with wtRas
overexpression was increased by LDL exposure. In contrast, RasN17
overexpression blocked this Ras activation in the LDL-treated samples
as well as untreated controls
(Figure 3C
, bottom). Furthermore, LDL caused Ras
translocation to the cell membrane, as detected by
immunoblotting, in wtRas-transfected cells (data not
shown). Therefore, LDL activates both endogenous
and overexpressed wtRas, but not the Ras mutant with low GTP affinity.
Dominant Negative Mutant of Ras Attenuates LDL
Activation of P38 and JNK
To elucidate the role of Ras in LDL activation of P38,
we infected HUVECs with an adenoviral construct, Ad-RasN17, to
overexpress RasN17. These cells, as well as control cells (infected
with adRSV-ß-gal), were then exposed to LDL. Cell lysates were
collected for ATF-2 and c-Jun phosphorylation assays.
In parallel experiments, cells were treated with PMA, thus serving as a
positive control. As shown in
Figure 4
, both LDL and PMA increased ATF-2 and c-Jun
phosphorylation in cells infected with Ad-ß-gal (top
2 panels). These effects were attenuated in cells infected with
Ad-RasN17. The results suggest that Ras plays an important role in the
signaling of LDL activation of p38 and JNK. Because PMA, but not LDL,
induced ERK1/2 phosphorylation in
ECs,9 the
inhibitory effect of RasN17 on PMA-induced ERK1/2
phosphorylation is shown in
Figure 4
, bottom.
|
Dominant Negative Mutant of Ras Attenuates the
LDL-Induced AP-1 Activation
Because mutant Ras blocks p38/ATF-2 and JNK/c-Jun
pathways and Jun/ATF-2 heterodimers bind to the AP-1 site in the
promoters of many genes (eg, the gene encoding
c-Jun),11 RasN17 should
attenuate LDL-induced AP-1 activation. To test this, we investigated
the modulation of AP-1 binding by LDL using electrophoretic mobility
shift assay in Ad-RasN17infected ECs. As shown in
Figure 5
, RasN17 abolished the LDL-induced increase in AP-1
binding and reduced the PMA-induced increase in AP-1 binding. Many
inducible molecules in ECs, eg, VCAM-1 and ICAM-1, contain a number of
AP-1like and NF-
Blike binding motifs within their 5' promoter
regions.4 18 19
Because LDL activated AP-1 but not
NF-
B,8 LDL-induced Ras-p38
and Ras-JNK pathways should have little effect on NF-
B activation.
PMA increased the binding activity of NF-
B, and this effect was not
blocked by Ad-RasN17 in ECs
(Figure 5
).
|
To test whether the blockage of p38 and JNK by RasN17 leads
to a similar outcome in LDL-induced AP-1 activation, we cotransfected
pAP-1-luc and RasN17 plasmids into HUVECs. The transfected cells were
then exposed to LDL. As shown in
Figure 6
, after RasN17 transfection, LDL no longer induced
AP-1 activation (P<0.01). The
basal level of AP-1 activity was also decreased in RasN17 transfection
samples compared with controls. Consequently, a Ras-dependent pathway
appears to be involved in the AP-1 activation by
LDL.
|
A Specific p38 Kinase Inhibitor
Blocks LDL-Induced E-Selectin
We previously reported that LDL increased
endothelial cell adhesiveness by inducing adhesion
molecules, including
E-selectin.6 To elucidate the
role of p38 in the induction of LDL-induced targeting genes, we chose
E-selectin as an example in ECs, because it is an ATF-2regulatory
gene.10 We exposed HUVECs to
LDL with or without SB203580, a specific p38 kinase
inhibitor, for 48 to 72 hours. Total RNA was collected from
various samples for Northern analysis. As shown in
Figure 7
, SB203580 blocked LDL-increased E-selectin mRNA in
both LDL exposure times. vWF mRNA was also detected as an
endothelial internal
control.
|
| Discussion |
|---|
|
|
|---|
Originally identified as a proto-oncogene, Ras has been broadly studied for its function and regulation. There is little information, however, on the physiological and pathophysiological roles of Ras in cardiovascular cells, especially in endothelium exposed to lipoprotein. As a small GTPase molecule, Ras moves to the plasma membrane after the synthesis in free cytoplasmic ribosomes and the farnesylation of its posttranslational C-terminal. Ras activation can trigger at least 3 diverging MAPK cascades, ie, p38, JNK, and ERK. Distinct intracellular MAPK signaling cascades are differentially activated to orchestrate transcriptional activation in response to various extracellular stimuli. LDL activates the membrane-associated Ras in human ECs, which in turn preferentially activates p38 and JNK, the 2 MAPKs particularly involved in stress responses. Both native LDL and oxidized LDL have been found to stimulate p44/42 and p38 MAPKs in smooth muscle cells and microphages.22 23 24 25 In contrast, neither native LDL nor Cu2+-oxidized LDL stimulates ERK activity in bovine aortic ECs.25 It is not clear why LDL causes this differential activation of MAPKs in ECs. Fluid shearing of vascular ECs increases the JNK activity by >10-fold but activates ERK to a much lesser degree.26 Osmotic pressure and UV irradiation also selectively activate the JNK pathway but not the ERK pathway.27 28 Ras can activate both Raf-1 and MEKKs. Raf-1 activates ERK but not JNK/p38, whereas MEKKs activate JNK/p38 but not ERK.29 Thus, LDL-stimulated Ras may activate MEKKs to a greater extent than Raf-1. Alternatively, other LDL-induced signaling pathways may inhibit Raf-1 signaling. cAMP inhibition of ERK activation by preventing Ras-dependent activation of Raf-1 has been reported.30 Indeed, LDL increased cAMP-responsive elementbinding protein binding and protein kinase A activation in ECs.8 Recently, the phosphatidylinositol 3-kinase (PI3K)Akt pathway was shown to inhibit the Raf-MEK-ERK pathway through Akt phosphorylation of Raf-1.31 32 The involvement of the PI3K-Akt pathway in the LDL-mediated EC activation remains to be studied. Regarding upstream signaling, Cdc42 and Rac-1, in addition to Ras, can also selectively activate JNK and p38.33 34 Thus, LDL may also activate JNK/p38 through Rho family GTPase-mediated signal transduction.
The guanine nucleotide exchange factors are important in Ras activation in response to growth factors, shear stress, and cytokines. In many instances, docking proteins such as Grb2/Sos are necessary for Ras activation. Sos is a cytoplasmic Ras-GEF that is constitutively associated with the adaptor protein Grb2. When Grb2 interacts with a tyrosine-phosphorylated membrane receptor, it positions Sos at the plasma membrane where it can promote activation of Ras. Alternatively, a tyrosine-phosphorylated Shc may serve as a bait for Grb2 docking and Sos activation. We detected no membrane translocation of these docking proteins in HUVECs at up to 6 hours of LDL exposure (Zhu et al, unpublished observation). Thus, LDL may activate Ras in ECs through a process independent of growth factor activation. Conversely, the elevated cellular cholesterol level resulting from LDL exposure could promote the membrane translocation of caveolin-1 and Ras, which is a caveolin-binding signaling molecule, into caveolae in human ECs.12 Thus, caveolin may play a role in LDL-mediated Ras activation.
E-selectin is an important adhesion molecule that is transiently and specifically expressed in ECs on stimulation with cytokines and LDL.6 35 E-selectin can serve as a marker for endothelial activation. ATF2 was reported to play an important role in the activation of the E-selectin promoter.10 LDL increases E-selectin at both the mRNA and protein levels6 8 and can increase the E-selectin promoter activity (Zhu et al, unpublished observation). Here, we report that a p38 kinase inhibitor attenuates LDL-induced E-selectin at the mRNA level. Thus, it appears likely that LDL activates the E-selectin promoter in ECs through the ATF-2dependent mechanism. The blocking effects of RasN17 on ATF-2 and c-Jun phosphorylation and AP-1 transactivation provide further evidence for the involvement of Ras in this transcriptional activation.
Collectively, the results of the present and previous studies show that LDL activates ECs predominantly through Ras-JNK/p38 signaling pathways. This supports our working hypothesis that LDL perturbs the cell membrane and activates membrane-associated proteins (eg, Ras), which, in turn, activate the JNK/p38 pathways. Subsequently, c-Jun and ATF-2 are activated and form a c-Jun/ATF-2 dimer to induce c-Jun expression via the TRE site at the Jun promoter. Accumulation of c-Jun by de novo synthesis consistently elevates the level of AP-1, which further chronically induces other specific cellular genes regulated by AP-1 (eg, ICAM-1 and E-selectin), leading to EC activation.
| Acknowledgments |
|---|
Received March 15, 2001; accepted April 27, 2001.
| References |
|---|
|
|
|---|
2. Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992;43:219225.[Medline] [Order article via Infotrieve]
3. Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest. 1998;101:10641075.[Medline] [Order article via Infotrieve]
4. Lin JH, Zhu Y, Liao HL, Kobari Y, Groszek L, Stemerman MB. Induction of vascular cell adhesion molecule-1 by low-density lipoprotein. Atherosclerosis. 1996;127:185194.[Medline] [Order article via Infotrieve]
5.
Haller H, Schaper
D, Ziegler W, Philipp S, Kuhlmann M, Distler A, Luft FC. Low-density
lipoprotein induces vascular adhesion molecule expression on human
endothelial cells.
Hypertension. 1995;25:511516.
6.
Smalley DM, Lin JH,
Curtis ML, Kobari Y, Stemerman MB, Pritchard KAJ. Native LDL increases
endothelial cell adhesiveness by inducing intercellular
adhesion molecule-1. Arterioscler Thromb
Vasc Biol. 1996;16:585590.
7. Ko Y, Totzke G, Seewald S, Schmitz U, Schiermeyer B, Meyer zu Brickwedde MK, Vetter H, Sachinidis A. Native low-density lipoprotein (LDL) induces the expression of the early growth response gene-1 in human umbilical arterial endothelial cells. Eur J Cell Biol. 1995;68:306312.[Medline] [Order article via Infotrieve]
8.
Zhu Y, Lin JH, Liao
HL, Friedli OJ, Verna L, Marten NW, Straus DS, Stemerman MB. LDL
induces transcription factor activator protein-1 in human
endothelial cells.
Arterioscler Thromb Vasc Biol. 1998;18:473480.
9. Zhu Y, Liao HL, Wang N, Friedli OJ, Verna L, Stemerman MB. Low-density lipoprotein activates Jun N-terminal kinase (JNK) in human endothelial cells. Biochim Biophys Acta. 1999;1436:557564.[Medline] [Order article via Infotrieve]
10.
De LL, Johnson
DR, Whitley MZ, Collins T, Pober JS. cAMP and tumor necrosis factor
competitively regulate transcriptional activation through and nuclear
factor binding to the cAMP-responsive element/activating transcription
factor element of the endothelial leukocyte adhesion
molecule-1 (E-selectin) promoter. J
Biol Chem. 1994;269:1919319196.
11. van Dam H, Duyndam M, Rottier R, Bosch A, de Vries-Smits L, Herrlich P, Zantema A, Angel P, van der Eb AJ. Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J. 1993;12:479487.[Medline] [Order article via Infotrieve]
12.
Zhu Y, Liao HL,
Wang N, Yuan Y, Ma K-S, Verna L, Stemerman MB. Low-density lipoprotein
promotes caveolin-1 and Ras translocation to caveolae: role of
cholesterol in endothelial signaling.
Arterioscler Thromb Vasc Biol. 2000;20:24652470.
13.
Gupta S, Campbell
D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the
JNK signal transduction pathway.
Science. 1995;267:389393.
14. Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol. 1997;17:23602371.[Abstract]
15. Jin G, Wu C-H, Li YS, Hu J, Shyy JY, Chien S. Effects of active and negative mutants of Ras on rat arterial neointima formation. J Surg Res.. 2000;94:124132.[Medline] [Order article via Infotrieve]
16.
Wang N, Verna L,
Hardy S, Forsayeth JR, Zhu Y, Stemerman MB. Adenovirus-mediated
overexpression of c-Jun and c-Fos induces intercellular adhesion
molecule-1 and monocyte chemoattractant protein-1 in human
endothelial cells.
Arterioscler Thromb Vasc Biol. 1999;19:20782084.
17. de RJ, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene. 1997;14:623625.[Medline] [Order article via Infotrieve]
18.
Degitz K, Li LJ,
Caughman SW. Cloning and characterization of the 5'-transcriptional
regulatory region of the human intercellular adhesion molecule 1 gene.
J Biol Chem. 1991;266:1402414030.
19.
Shyy JY, Lin MC,
Han J, Lu Y, Petrime M, Chien S. The cis-acting phorbol ester
"12-O-tetradecanoylphorbol
13-acetate"-responsive element is involved in shear stress-induced
monocyte chemotactic protein 1 gene expression.
Proc Natl Acad Sci
U S A. 1995;92:80698073.
20.
Cybulsky MI,
Gimbrone MAJ. Endothelial expression of a mononuclear
leukocyte adhesion molecule during atherogenesis.
Science. 1991;251:788791.
21.
Li H, Cybulsky
MI, Gimbrone MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a
cytokine-regulatable mononuclear leukocyte adhesion molecule,
in rabbit aortic endothelium.
Arterioscler Thromb. 1993;13:197204.
22.
Sachinidis A,
Kettenhofen R, Seewald S, Gouni-Berthold I, Schmitz U, Seul C, Ko Y,
Vetter H. Evidence that lipoproteins are carriers of bioactive factors.
Arterioscler Thromb Vasc Biol. 1999;19:24122421.
23.
Metzler B, Li C,
Hu Y, Sturm G, Ghaffari-Tabrizi N, Xu Q. LDL stimulates
mitogen-activated protein kinase phosphatase-1 expression,
independent of LDL receptors, in vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol. 1999;19:18621871.
24.
Auge N,
Escargueil-Blanc I, Lajoie-Mazenc I, Suc I, Andrieu-Abadie N, Pieraggi
MT, Chatelut M, Thiers JC, Jaffrezou JP, Laurent G, Levade T,
Negre-Salvayre A, Salvayre R. Potential role for ceramide in
mitogen-activated protein kinase activation and proliferation
of vascular smooth muscle cells induced by oxidized low density
lipoprotein. J Biol Chem. 1998;273:1289312900.
25.
Kusuhara M, Chait
A, Cader A, Berk BC. Oxidized LDL stimulates mitogen-activated
protein kinases in smooth muscle cells and macrophages.
Arterioscler Thromb Vasc Biol. 1997;17:141148.
26. Li YS, Shyy JY, Li S, Lee J, Su B, Karin M, Chien S. The Ras-JNK pathway is involved in shear-induced gene expression. Mol Cell Biol. 1996;16:59475954.[Abstract]
27.
Galcheva-Gargova
Z, Derijard B, Wu IH, Davis RJ. An osmosensing signal transduction
pathway in mammalian cells.
Science. 1994;265:806808.
28.
Hibi M, Lin A,
Smeal T, Minden A, Karin M. Identification of an oncoprotein- and
UV-responsive protein kinase that binds and potentiates the c-Jun
activation domain. Genes Dev. 1993;7:21352148.
29.
Minden A, Lin A,
McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M.
Differential activation of ERK and JNK mitogen-activated
protein kinases by Raf-1 and MEKK.
Science. 1994;266:17191723.
30.
Cook SJ,
McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf.
Science. 1993;262:10691072.
31.
Rommel C, Clarke
BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos
GD, Glass DJ. Differentiation stage-specific inhibition of the
Raf-MEK-ERK pathway by Akt.
Science. 1999;286:17381741.
32.
Zimmermann S,
Moelling K. Phosphorylation and regulation of Raf by
Akt (protein kinase B).
Science. 1999;286:17411744.
33. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell. 1995;81:11471157.[Medline] [Order article via Infotrieve]
34.
Bagrodia S,
Derijard B, Davis RJ, Cerione RA. Cdc42 and PAK-mediated signaling
leads to Jun kinase and p38 mitogen-activated protein kinase
activation. J Biol Chem. 1995;270:2799527998.
35. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin-1 activation of vascular endothelium: effects on procoagulant activity and leukocyte adhesion. Am J Pathol. 1985;121:394403.[Abstract]
This article has been cited by other articles:
![]() |
N. Bulat, G. Waeber, and C. Widmann LDLs stimulate p38 MAPKs and wound healing through SR-BI independently of Ras and PI3 kinase J. Lipid Res., January 1, 2009; 50(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. V. Sangle, R. Zhao, and G. X. Shen Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1243 - E1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ju, D. J. Behm, S. Nerurkar, M. E. Eybye, R. E. Haimbach, A. R. Olzinski, S. A. Douglas, and R. N. Willette p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 932 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dobreva, G. Waeber, V. Mooser, R. W. James, and C. Widmann LDLs induce fibroblast spreading independently of the LDL receptor via activation of the p38 MAPK pathway J. Lipid Res., December 1, 2003; 44(12): 2382 - 2390. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kalyankrishna and K. U. Malik Norepinephrine-Induced Stimulation of p38 Mitogen-Activated Protein Kinase Is Mediated by Arachidonic Acid Metabolites Generated by Activation of Cytosolic Phospholipase A2 in Vascular Smooth Muscle Cells J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 761 - 772. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |